About MAMA
The MAMA Study is designed to find out whether it is better for women who have inflammatory arthritis and are pregnant to temporarily stop or to continue taking biologic medications. Currently, both continuing and stopping using biologics beyond 28 weeks of pregnancy are routine practice in the UK; this varies between different hospitals around the UK. The MAMA Study is looking to provide an answer on which is the better approach for women and their babies.
Study overview
Women who take part in the MAMA Study will be randomly allocated by a computer system to one of the following groups:
The continuing group. Women in this group will continue taking their biologic thoughout pregnancy.
OR
The stopping group. Women in this group will stop their biologics before the third trimester (28 weeks) of pregnancy, and restart no earlier than 2 weeks post-pregnancy.
While we encourage you to stay in your allocated group, you would be able to restart your biologic if you needed to at any time, such as during an arthritis flare.
Other than stopping or continuing your current biologic by 28 weeks' gestation, no other changes will be made to your arthritis treatment as a result of being in this study.
There are short questionnaires to fill out when you join the study, monthly during pregnancy and at 3, 6, 12, and 24 months after your baby is born. These questionnaires will ask you about your arthritis symptoms and treatment, and about you and your child's health and quality of life.
Your baby's involvement
There will also be an option for your baby to be considered for another part of the study looking at your baby's immune system. You can find out about this optional part of the study on the Infant Immune Response page on the MAMA Website.
How can I take part in MAMA?
You can find out more about the study in the MAMA Participant Information Leaflet or by watching the MAMA Information Video.
If you have any questions at all please get in touch with the MAMA Team, we'd love to hear from you, even if it is just for an informal chat.
For the answers to Frequently Asked Questions please visit our FAQs page
